Synthesis and characterization of bis[dicarboxylatotetraorganodistannoxane] units involving 5-[(E)-2-(aryl)-1-diazenyl]-2-hydroxybenzoic acids: An investigation of structures by X-ray diffraction, NMR, electrospray ionisation MS and assessment of in vitro cytotoxicity

Synthesis and characterization of some diorganotin(IV) complexes of Schiff bases derived from a non‐protein amino acid. Crystal structures of {HO2CC6H4[NC(H)}{C(CH3)CH(CH3)‐3‐OH]‐p} and its di‐n‐butyltin(IV) complex (nBu2Sn{O2CC6H4[NC(H)}{C(CH3)CH(CH3)‐3‐OH]‐p}2)

“…The complexity of the tin NMR spectra also suggests dissociation in solution or formation of different isomers. [31] Although it is difficult to assign coordination numbers and geometry with certainty to the tin atoms on the basis of their 119 Sn chemical shifts, values of δ ( 119 Sn) in the ranges −200 to −400, −90 to −190 and 200 to −60 ppm have been associated with six-, five-and fourcoordinated tin centers bearing n-butyl groups, respectively. [32] (a) (b) If two of the peaks found in the spectra of 3 and 5 are considered to be due to endo and exo species, the other two, which are very close to each other and smaller in intensities, but different with respect to those found in 2 and 4, could be assigned to different isomeric forms.…”

Triphenyltin(IV) 2-[(E)-2-(aryl)-1-diazenyl]benzoates as anticancer drugs: synthesis, structural characterization, in vitro cytotoxicity and study of its influence towards the mechanistic role of some key enzymes

“…In view of the increasing interest in organotin(IV) carboxylates, a few organotin(IV) complexes of Schiff bases derived from amino acids have also been investigated extensively [24][25][26][27][28][29][30][31][32][33][34][35] and the in vitro cytotoxicity results demonstrated that triphenyltin(IV) compounds are generally more active than CDDP (cisplatin) [34,35]. On the other hand, examples of organotin(IV) carboxylate containing -N=N-skeleton are scanty except for the recent ones on the diorganotin(IV) compounds of the formulations n Bu 2 Sn(LH) 2 and {[ n Bu 2 Sn(LH) 2 ] 2 O} 2 (LH=5-[(E)-2-(aryl)-1-diazenyl]-2-hydroxybenzoate) and the in vitro cytotoxic results were quite promising at least with respect to the some of the standard drugs [36,37]. Recently, three triphenyltin(IV) compounds involving the 2-{[(2Z)-(3-hydroxy-1-methyl-2-butenylidene)]amino}-4-methyl-pentanoate and 2-{[(E)-1-(2-hydroxyphenyl)-alkylidene]amino}-4-methyl-pentanoate skeletons showed encouraging cytotoxic activity across a panel of cell lines [35] and this has prompted us to investigate related systems by modifying the ligand part of the molecule, which might improve dissolution properties and thereby influence cytotoxicity.…”

“…3The structure of Ph 3 SnL 2 H (2) obtained after full geometry optimization hydroxybenzoate which contains an -N=N-group[36,37]. The cytotoxic results of the di-butyltin(IV) compounds of formulation {[Bu 2 Sn(LH) 2 ] 2 O} 2 displayed more activity than the compound of the type Bu 2 Sn(LH) 2 and the ID 50 values were found to be superior to most of the standard drugs against all seven human cancer cell lines(Table 2).…”

“…The cytotoxic results of the di-butyltin(IV) compounds of formulation {[Bu 2 Sn(LH) 2 ] 2 O} 2 displayed more activity than the compound of the type Bu 2 Sn(LH) 2 and the ID 50 values were found to be superior to most of the standard drugs against all seven human cancer cell lines(Table 2). It should be mentioned here that the {[Bu 2 Sn(LH) 2 ] 2 O} 2 type of complexes comprise of a centrosymmetric tetranuclear bis (dicarboxylatotetrabutyldistannoxane) frame-work which contain a planar Sn 4 O 2 core in which two μ 3 -oxo O-atoms connect an Sn 2 O 2 ring to two exocyclic Sn-atoms[37]. This encouraging cytotoxic effect of the di-butyltin(IV) compounds of formulation {[Bu 2 Sn(LH) 2 ] 2 O} 2 also possess -N=N-group.…”

Dibutyltin(IV) complexes containing arylazobenzoate ligands: chemistry, in vitro cytotoxic effects on human tumor cell lines and mode of interaction with some enzymes

“…Similar observations were also noted recently for the ruthenium complexes containing azo-ligands which have shown higher activity in comparison to the complexes with non-azo ligands [27]. On the other hand, examples of diorganotin(IV) arylazobenzoates of formulations R 2 Sn(L) 2 and {[R 2 Sn(L)] 2 O} 2 are scanty except for the recent ones where L=5-[(E)-2-(aryl)-1-diazenyl]-2-hydroxybenzoate, for which in vitro cytotoxic results were found to be quite promising at least with respect to some of the standard drugs [28,29].…”